JAMA & ARCHIVES
Arch Fam Med
SEARCH
GO TO ADVANCED SEARCH
HOME  PAST ISSUES  TOPIC COLLECTIONS  CME  PHYSICIAN JOBS  CONTACT US  HELP
Institution: CLOCKSS  | My Account | E-mail Alerts | Access Rights | Sign In
  Vol. 8 No. 3, May 1999 TABLE OF CONTENTS
  Archives
  •  Online Features
  Clinical Review
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (17)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Men's Health
 •Men's Health, Other
 •Alert me on articles by topic

Current Status of Testosterone Replacement Therapy in Men

Stephen J. Winters, MD

Arch Fam Med. 1999;8:257-263.

Testosterone plays an essential role in the development of the normal male and in the maintenance of many male characteristics, including muscle mass and strength, bone mass, libido, potency, and spermatogenesis. Androgen deficiency occurs with disorders that damage the testes, including traumatic or surgical castration (primary testicular failure) or disorders in which the gonadotropin stimulation of the testes is reduced (hypogonadotropic hypogonadism). The clinical manifestations of androgen deficiency depend on the age at onset and the severity and duration of the deficiency. In adult males, these manifestations may include reduced body hair, decreased muscle mass and strength, increased fat mass, decreased hematocrit, decreased libido, erectile dysfunction, infertility, osteoporosis, and depressed mood. The forms of androgen replacement currently available in the United States are intramuscular depot injections of testosterone esters, oral tablets of testosterone derivatives, and transdermal patches. For most patients, androgen replacement therapy with testosterone is a safe, effective treatment for testosterone deficiency.


From the Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pa.


RELATED ARTICLE

The Archives of Family Medicine Continuing Medical Education Program
Arch Fam Med. 1999;8(3):207-209.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Impact of IGF-I and CYP19 Gene Polymorphisms on the Survival of Patients With Metastatic Prostate Cancer
Tsuchiya et al.
JCO 2006;24:1982-1989.
ABSTRACT | FULL TEXT  

Population variation in age-related decline in male salivary testosterone
Ellison et al.
Hum Reprod 2002;17:3251-3253.
ABSTRACT | FULL TEXT  

Andropause: Knowledge and Perceptions Among the General Public and Health Care Professionals
Anderson et al.
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2002;57:M793-796.
ABSTRACT | FULL TEXT  

Testosterone in Aging Men
Applegate and Winters
Arch Fam Med 2000;9:221-221.
FULL TEXT  

Testosterone reduces neuronal secretion of Alzheimer's beta -amyloid peptides
Gouras et al.
Proc. Natl. Acad. Sci. USA 2000;97:1202-1205.
ABSTRACT | FULL TEXT  




HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1999 American Medical Association. All Rights Reserved.